BJMO - 2020, issue Special, march 2020
Tom Feys MBA, MSc, J. Beekwilder PhD
Over the last decades, the comprehensive molecular characterization of non-small-cell lung cancer (NSCLC) has expanded our understanding of the cellular origins and molecular pathways affected in this lung cancer subtype. Many of these genetic alterations represent potential therapeutic targets for which new drugs are constantly under development. As such, targeted therapy has emerged as the therapeutic cornerstone for patients with oncogene-driven advanced NSCLC. This personalized treatment strategy not only improved the treatment outcomes compared to traditional chemotherapy, it also had a significant impact on the quality of life of patients. Nowadays, targeted agents directed against epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase rearrangements have become standard therapy for patients harbouring these genetic aberrations. In addition to this, targeted agents directed against other, more rare, genetic aberrations (e.g. ROS1, NTRK, MET, RET, etc.) have generated promising results and several of these agents will enter the NSCLC treatment arsenal in the near future. This article provides an overview of key studies in patients with oncogene-driven NSCLC that were presented in the past year.
Read moreBJMO - 2020, issue Special, march 2020
Tom Feys MBA, MSc, J. Beekwilder PhD
Radiotherapy (RT) plays a key role in the management of lung cancer and it is used at least once in over half of patients in both the curative and palliative setting. In recent years, the role of RT in the management of thoracic tumours is rapidly evolving. In this article we provide a brief overview of important RT developments in the past year.
Read moreBJMO - volume 13, issue 3, may 2019
Tom Feys MBA, MSc, J. Beekwilder PhD
The 2019 annual American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium was held from February 14-16 in San Francisco. The Belgian Multidisciplinary Meeting on Urological Cancers (BMUC) organised a post-ASCO GU regional tour during which the highlights of the 2019 ASCO GU meeting were discussed. This tour featured four different meetings in four locations in Belgium: Namur, Ghent, Nivelles and Paal. This summary will specifically report on the meeting held in Ghent during which prof. dr Piet Ost (Ghent University Hospital) and prof. dr Sylvie Rottey (Ghent University Hospital) gave a summary of the most important advances in the treatment of prostate, bladder and renal cancer.
(BELG J MED ONCOL 2019;13(3):109–114)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
